pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›cabozantinib
drug · small molecule
save

cabozantinib

pre_registrationupdated 6mo ago
by Lotus Pharmaceutical Co Ltd🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval48 co-mentions · 24 sources
  • drugCABOMETYX48 co-mentions · 24 sources
  • drugCOMETRIQ48 co-mentions · 24 sources
  • drugcabozantinib s-malate48 co-mentions · 24 sources
  • tagSmall Molecule24 co-mentions · 24 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 41 investigational indications.

targets

Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2

all catalysts(0)

nothing on the calendar yet

Trials studying cabozantinib

  • phase3A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)active not recruitingn=747
  • phase2Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCrecruitingn=100
  • phase3Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinomarecruitingn=720
  • phase2A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)recruitingn=474
  • phase2A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)recruitingn=43
  • phase2Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitorscompletedn=127
  • phase1A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumorsrecruitingn=362
  • phase1A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)not yet recruitingn=112

News(2)

  • Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think so
    When Exelixis CEO Michael Morrissey rolled out the biotech's final numbers for 2025 earlier in the year, there was no mistaking the outsized role that cabozantinib played in funding the company and…
    endpoints · 3mo ago
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 6mo ago
generic
cabozantinib
MOA
Hepatocyte growth factor receptor inhibitor; Vascular endothelial growth factor receptor 2 inhibitor
indication
Hepatocellular Carcinoma
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?